Cai W, Counsell R E, Schteingart D E, Sinsheimer J E, Vaz A D, Wotring L L
College of Pharmacy, University of Michigan, Ann Arbor 48109-1065, USA.
Cancer Chemother Pharmacol. 1997;39(6):537-40. doi: 10.1007/s002800050610.
Mitotane (o,p'-DDD), is the only adrenolytic agent available for the treatment of adrenocortical carcinoma. Previous studies have shown that mitotane covalently binds to adrenal proteins following its metabolism in adrenocortical tissue to a reactive acyl chloride intermediate. It was the objective of this study to compare the electrophoresis separation patterns of such adducts following activation of mitotane by various adrenocortical sources.
With the use of a 125I-labeled analog of mitotane, 1-(2-chlorophenyl)-1-(4-iodophenyl)-2,2-dichloroethane, gel electrophoresis patterns were obtained for homogenates from bovine, canine and human adrenocortical preparations as well as from a human adrenal preparation. Western immunoblotting analysis was used to test the resulting patterns for adducts of cytochrome P-450scc and adrenodoxin.
The electrophoresis separations were similar for all preparations, with bands at apparent molecular weights of 49.5 and 11.5 kDa being the most pronounced. Radiolabeling of the proteins of a human adrenal cancer cell line NCI H-295 was weak, but a band at 11.5 kDa was detected. Western immunoblotting analyses indicated that the band at 49.5 kDa corresponded in molecular weight to that of adrenal cytochrome P-450scc, but the band at 11.5 kDa did not correspond to adrenodoxin.
The similarity of the results with canine and bovine adrenal preparations to that of human material offers useful systems for studying mitotane and its analogs. This should aid in understanding the mechanism of action of mitotane and in the design of compounds for the treatment of adrenocortical carcinoma.
米托坦(邻,对'-滴滴滴)是唯一可用于治疗肾上腺皮质癌的肾上腺溶解剂。先前的研究表明,米托坦在肾上腺皮质组织中代谢为反应性酰氯中间体后,会与肾上腺蛋白共价结合。本研究的目的是比较米托坦经各种肾上腺皮质来源激活后此类加合物的电泳分离模式。
使用米托坦的125I标记类似物1-(2-氯苯基)-1-(4-碘苯基)-2,2-二氯乙烷,获得了来自牛、犬和人肾上腺皮质制剂以及人肾上腺制剂匀浆的凝胶电泳图谱。采用蛋白质免疫印迹分析来检测细胞色素P-450scc和肾上腺铁氧化还原蛋白加合物的所得图谱。
所有制剂的电泳分离结果相似,最明显的条带出现在表观分子量为49.5 kDa和11.5 kDa处。人肾上腺癌细胞系NCI H-295蛋白质的放射性标记较弱,但检测到一条11.5 kDa的条带。蛋白质免疫印迹分析表明,49.5 kDa处的条带分子量与肾上腺细胞色素P-450scc相对应,但11.5 kDa处的条带与肾上腺铁氧化还原蛋白不对应。
犬和牛肾上腺制剂的结果与人材料的结果相似,为研究米托坦及其类似物提供了有用的系统。这应有助于理解米托坦的作用机制以及设计用于治疗肾上腺皮质癌的化合物。